FDA declares semaglutide shortage resolved — compounded semaglutide products must cease by November 2026

The FDA's removal of semaglutide from its drug shortage database ↗ triggers automatic legal consequences for compounders. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding of a commercially available drug is only permitted when that drug is on the FDA shortage list or when there is a patient-specific medical need that cannot be met by the approved product. With the shortage resolved, both 503A traditional compounding pharmacies and 503B outsourcing facilities were given until 19 November 2026 to cease production of all semaglutide-containing compounds. Patients are directed to transition to FDA-approved Ozempic (semaglutide 0.5, 1, 2 mg) or Wegovy (semaglutide 2.4 mg) — see our counterfeit Ozempic alert.

Semaglutide was first added to the FDA shortage list in 2022 following explosive demand for Ozempic (for T2DM) and Wegovy (for chronic weight management) driven by cardiovascular outcome trial data and high-profile media coverage. At the peak, an estimated 3–5 million patients in the US were using compounded semaglutide — at prices averaging $200–$400/month vs $900–$1,300/month for branded products. Compounders added L-arginine, cyanocobalamin (B12), NAD+, and other excipients not present in FDA-approved formulations, raising safety and efficacy concerns. The FDA issued multiple warnings about unverified compounded formulations and received reports of dosing errors and adverse events ↗ associated with compounded products. Related: ESC cardiovascular guidelines for GLP-1 RAs.

Multiple compounding industry groups, including the Outsourcing Facilities Association (OFA) and the Alliance for Pharmacy Compounding, filed for emergency injunctions to delay the wind-down, citing patient access hardship. As of October 2026, courts had declined to issue injunctions in most jurisdictions, with judges noting that the FDA's shortage determination was within its statutory authority. Patient advocacy groups raised concerns about insurance coverage gaps — many patients who transitioned from compounded to branded semaglutide found their insurers required step therapy (failed diet/exercise documentation) before covering Wegovy. The CMS Medicare coverage database ↗ notes that Wegovy is not currently covered under standard Medicare Part D. See our drug coverage guide.

Compounded semaglutide differed from approved products in important ways: formulation (subcutaneous vs approved device), concentration (some compounders provided higher concentrations requiring different injection volumes), and added ingredients with uncharacterised interactions. Novo Nordisk's approved products use a specific pH-buffered formulation with sodium phosphate dibasic dihydrate that is optimised for subcutaneous depot formation and absorption. Pharmaceutical equivalence cannot be assumed for compounded versions. The FDA pharmacokinetic comparison is documented in product labelling ↗. Related: Ozempic CV label update and generic vs brand-name drugs guide.